{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:48:23Z","timestamp":1759063703037},"reference-count":71,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2008,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Adefovir dipivoxil (ADV) and tenofovir disoproxil fumarate (TDF) are nucleotide analogs that inhibit the replication of wild-type hepatitis B virus (HBV) and lamivudine (3TC)-resistant virus in HBV-infected patients, including those who are coinfected with human immunodeficiency virus. The combination of ADV or TDF with other nucleoside analogs is a proposed strategy for managing antiviral drug resistance during the treatment of chronic HBV infection. The antiviral effect of oral ADV or TDF, alone or in combination with 3TC or emtricitabine (FTC), against chronic woodchuck hepatitis virus (WHV) infection was evaluated in a placebo-controlled study in the woodchuck, an established and predictive model for antiviral therapy. Once-daily treatment for 48 weeks with ADV plus 3TC or TDF plus FTC significantly reduced serum WHV viremia levels from the pretreatment level by 6.2 log<jats:sub>10<\/jats:sub>and 6.1 log<jats:sub>10<\/jats:sub>genome equivalents\/ml serum, respectively, followed by TDF plus 3TC (5.6 log<jats:sub>10<\/jats:sub>genome equivalents\/ml), ADV alone (4.8 log<jats:sub>10<\/jats:sub>genome equivalents\/ml), ADV plus FTC (one survivor) (4.4 log<jats:sub>10<\/jats:sub>genome equivalents\/ml), TDF alone (2.9 log<jats:sub>10<\/jats:sub>genome equivalents\/ml), 3TC alone (2.7 log<jats:sub>10<\/jats:sub>genome equivalents\/ml), and FTC alone (2.0 log<jats:sub>10<\/jats:sub>genome equivalents\/ml). Individual woodchucks across all treatment groups also demonstrated pronounced declines in serum WHV surface antigen, characteristically accompanied by declines in hepatic WHV replication and the hepatic expression of WHV antigens. Most woodchucks had prompt recrudescence of WHV replication after drug withdrawal, but individual woodchucks across treatment groups had sustained effects. No signs of toxicity were observed for any of the drugs or drug combinations administered. In conclusion, the oral administration of 3TC, FTC, ADV, and TDF alone and in combination was safe and effective in the woodchuck model of HBV infection.<\/jats:p>","DOI":"10.1128\/aac.00654-08","type":"journal-article","created":{"date-parts":[[2008,8,2]],"date-time":"2008-08-02T01:55:36Z","timestamp":1217642136000},"page":"3617-3632","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":33,"title":["Antiviral Effects of Lamivudine, Emtricitabine, Adefovir Dipivoxil, and Tenofovir Disoproxil Fumarate Administered Orally Alone and in Combination to Woodchucks with Chronic Woodchuck Hepatitis Virus Infection"],"prefix":"10.1128","volume":"52","author":[{"given":"Stephan","family":"Menne","sequence":"first","affiliation":[{"name":"Gastrointestinal Unit, Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D.","family":"Butler","sequence":"additional","affiliation":[{"name":"Gastrointestinal Unit, Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea L.","family":"George","sequence":"additional","affiliation":[{"name":"Gastrointestinal Unit, Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilia A.","family":"Tochkov","sequence":"additional","affiliation":[{"name":"Gastrointestinal Unit, Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuao","family":"Zhu","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., 4 University Place, 4611 University Drive, Durham, North Carolina 27707"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelly","family":"Xiong","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., 4 University Place, 4611 University Drive, Durham, North Carolina 27707"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Gerin","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Georgetown University Medical Center, Washington, DC 20057"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Cote","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Georgetown University Medical Center, Washington, DC 20057"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bud C.","family":"Tennant","sequence":"additional","affiliation":[{"name":"Gastrointestinal Unit, Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1007\/s10620-006-9718-8","volume":"52","year":"2007","unstructured":"Akyildiz, M., F. Gunsar, G. Ersoz, Z. Karasu, T. Ilter, Y. Batur, and U. Akarca. 2007. Adefovir dipivoxil alone or in combination with lamivudine for three months in patients with lamivudine resistant compensated chronic hepatitis B. Dig. Dis. Sci.52:3444-3447.","journal-title":"Dig. Dis. Sci."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00939-9"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0140-6736(01)05840-8","volume":"358","year":"2001","unstructured":"Benhamou, Y., M. Bochet, V. Thibault, V. Calvez, M. H. Fievet, P. Vig, C. S. Gibbs, C. Brosgart, J. Fry, H. Namini, C. Katlama, and T. Poynard. 2001. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet358:718-723.","journal-title":"Lancet"},{"key":"e_1_3_2_5_2","first-page":"62","volume":"44","year":"2006","unstructured":"Benhamou, Y., V. Thibault, P. Vig, V. Calvez, A. G. Marcelin, M. H. Fievet, G. Currie, C. G. Chang, L. Biao, S. Xiong, C. Brosgart, and T. Poynard. 2006. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J. Hepatol.44:62-67.","journal-title":"J. Hepatol."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200301093480218"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1086\/514750","volume":"28","year":"1999","unstructured":"Bessesen, M., D. Ives, L. Condreay, S. Lawrence, and K. E. Sherman. 1999. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin. Infect. Dis.28:1032-1035.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/00002030-200303280-00028","volume":"17","year":"2003","unstructured":"Bruno, R., P. Sacchi, C. Zocchetti, V. Ciappina, M. Puoti, and G. Filice. 2003. Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus \u2018e-minus\u2019 patients with YMDD mutations after 4 weeks of tenofovir therapy. AIDS17:783-784.","journal-title":"AIDS"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/324003"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"R951","DOI":"10.1152\/ajpregu.2001.281.3.R951","volume":"281","year":"2001","unstructured":"Concannon, P., K. Levac, R. Rawson, B. Tennant, and A. Bensadoun. 2001. Seasonal changes in serum leptin, food intake, and body weight in photoentrained woodchucks. Am. J. Physiol. Regul. Integr. Comp. Physiol.281:R951-R959.","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1095\/biolreprod57.5.1008","volume":"57","year":"1997","unstructured":"Concannon, P., P. Roberts, B. Baldwin, and B. Tennant. 1997. Long-term entrainment of circannual reproductive and metabolic cycles by Northern and Southern Hemisphere photoperiods in woodchucks (Marmota monax). Biol. Reprod.57:1008-1015.","journal-title":"Biol. Reprod."},{"key":"e_1_3_2_12_2","first-page":"R1401","volume":"277","year":"1999","unstructured":"Concannon, P. W., V. D. Castracane, R. E. Rawson, and B. C. Tennant. 1999. Circannual changes in free thyroxine, prolactin, testes, and relative food intake in woodchucks, Marmota monax. Am. J. Physiol.277:R1401-R1409.","journal-title":"Am. J. Physiol."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510310128"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1089\/vim.1993.6.161"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.10.2740-2745.2001"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.10.2076"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.antiviral.2007.02.003","volume":"75","year":"2007","unstructured":"Dai, C. Y., W. L. Chuang, M. Y. Hsieh, L. P. Lee, J. F. Huang, N. J. Hou, Z. Y. Lin, S. C. Chen, L. Y. Wang, J. F. Tsai, W. Y. Chang, and M. L. Yu. 2007. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B. Antivir. Res.75:146-151.","journal-title":"Antivir. Res."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.10.3702-3710.2004"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/380398"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042957"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021812"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/319368","volume":"32","year":"2001","unstructured":"Hoff, J., F. Bani-Sadr, M. Gassin, and F. Raffi. 2001. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin. Infect. Dis.32:963-969.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.11.2804"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/095632020201300303","volume":"13","year":"2002","unstructured":"Hurwitz, S. J., B. C. Tennant, B. E. Korba, I. Liberman, J. L. Gerin, and R. F. Schinazi. 2002. Viral pharmacodynamic model for (\u2212)-beta-2\u2032,3\u2032-dideoxy-5-fluoro-3\u2032-thiacytidine (emtricitabine) in chronically infected woodchucks. Antivir. Chem. Chemother.13:165-176.","journal-title":"Antivir. Chem. Chemother."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2004.03.005"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2893.2006.00797.x","volume":"14","year":"2007","unstructured":"Jain, M. K., L. Comanor, C. White, P. Kipnis, C. Elkin, K. Leung, A. Ocampo, N. Attar, P. Keiser, and W. M. Lee. 2007. Treatment of hepatitis B with lamivudine and tenofovir in HIV\/HBV-coinfected patients: factors associated with response. J. Viral Hepat.14:176-182.","journal-title":"J. Viral Hepat."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(99)00072-8"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1053\/he.2000.5982"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1177\/135965350400900611","volume":"9","year":"2004","unstructured":"Korba, B. E., P. J. Cote, S. Menne, I. Toshkov, B. H. Baldwin, F. V. Wells, B. C. Tennant, and J. L. Gerin. 2004. Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection. Antivir. Ther.9:937-952.","journal-title":"Antivir. Ther."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.6.1757-1760.2000"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00017-5"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000171404.07995.5c"},{"key":"e_1_3_2_33_2","first-page":"67","volume":"12","year":"2001","unstructured":"Liaw, Y. F. 2001. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir. Chem. Chemother.12(Suppl. 1):67-71.","journal-title":"Antivir. Chem. Chemother."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21513"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2005.00599.x"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020681"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1998.9150"},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jhep.2004.09.017","volume":"42","year":"2005","unstructured":"Maynard, M., P. Parvaz, S. Durantel, M. Chevallier, P. Chevallier, M. Lot, C. Trepo, and F. Zoulim. 2005. Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure. J. Hepatol.42:279-281.","journal-title":"J. Hepatol."},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00325-07"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i1.104"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.7.2720-2728.2005"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.11.5305-5314.2002"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70102-6"},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","first-page":"F7","DOI":"10.1097\/00002030-200301030-00002","volume":"17","year":"2003","unstructured":"Nelson, M., S. Portsmouth, J. Stebbing, M. Atkins, A. Barr, G. Matthews, D. Pillay, M. Fisher, M. Bower, and B. Gazzard. 2003. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS17:F7-F10.","journal-title":"AIDS"},{"key":"e_1_3_2_45_2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/QAD.0b013e3282f303bf","volume":"22","year":"2008","unstructured":"Nuesch, R., J. Ananworanich, P. Srasuebkul, P. Chetchotisakd, W. Prasithsirikul, W. Klinbuayam, A. Mahanontharit, T. Jupimai, K. Ruxrungtham, and B. Hirschel. 2008. Interruptions of tenofovir\/emtricitabine-based antiretroviral therapy in patients with HIV\/hepatitis B virus co-infection. AIDS22:152-154.","journal-title":"AIDS"},{"key":"e_1_3_2_46_2","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1097\/00002030-200211220-00023","volume":"16","year":"2002","unstructured":"Nunez, M., M. Perez-Olmeda, B. Diaz, P. Rios, J. Gonzalez-Lahoz, and V. Soriano. 2002. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS16:2352-2354.","journal-title":"AIDS"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.20899"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.10.051"},{"key":"e_1_3_2_49_2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/135965350701200309","volume":"12","year":"2007","unstructured":"Qi, X., S. Xiong, H. Yang, M. Miller, and W. E. Delaney IV. 2007. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir. Ther.12:355-362.","journal-title":"Antivir. Ther."},{"key":"e_1_3_2_50_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hep.21534","volume":"45","year":"2007","unstructured":"Rapti, I., E. Dimou, P. Mitsoula, and S. J. Hadziyannis. 2007. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology45:307-313.","journal-title":"Hepatology"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1086\/345770"},{"key":"e_1_3_2_52_2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/lt.20981","volume":"13","year":"2007","unstructured":"Schiff, E., C. L. Lai, S. Hadziyannis, P. Neuhaus, N. Terrault, M. Colombo, H. Tillmann, D. Samuel, S. Zeuzem, J. P. Villeneuve, S. Arterburn, K. Borroto-Esoda, C. Brosgart, and S. Chuck. 2007. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl.13:349-360.","journal-title":"Liver Transpl."},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.6.1842-1852.2003"},{"key":"e_1_3_2_54_2","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jhep.2007.12.026","volume":"48","year":"2008","unstructured":"Sung, J. J., J. Y. Lai, S. Zeuzem, W. C. Chow, E. J. Heathcote, R. P. Perrillo, C. L. Brosgart, M. A. Woessner, S. A. Scott, D. F. Gray, and S. D. Gardner. 2008. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J. Hepatol.48:728-735.","journal-title":"J. Hepatol."},{"key":"e_1_3_2_55_2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jhep.2007.09.020","volume":"48","year":"2008","unstructured":"Tan, J., B. Degertekin, S. N. Wong, M. Husain, K. Oberhelman, and A. S. Lok. 2008. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J. Hepatol.48:391-398.","journal-title":"J. Hepatol."},{"key":"e_1_3_2_56_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0166-3542(02)00019-0","volume":"55","year":"2002","unstructured":"Tatti, K. M., B. E. Korba, H. L. Stang, S. Peek, J. L. Gerin, B. C. Tennant, and R. F. Schinazi. 2002. Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine. Antivir. Res.55:141-150.","journal-title":"Antivir. Res."},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1089-3261(05)70067-2"},{"key":"e_1_3_2_58_2","first-page":"179","volume":"28","year":"1998","unstructured":"Tennant, B. C., B. H. Baldwin, L. A. Graham, M. A. Ascenzi, W. E. Hornbuckle, P. H. Rowland, I. A. Tochkov, A. E. Yeager, H. N. Erb, J. M. Colacino, C. Lopez, J. A. Engelhardt, R. R. Bowsher, F. C. Richardson, W. Lewis, P. J. Cote, B. E. Korba, and J. L. Gerin. 1998. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology28:179-191.","journal-title":"Hepatology"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.09.043"},{"key":"e_1_3_2_60_2","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1053\/jlts.2002.35784","volume":"8","year":"2002","unstructured":"Terrault, N. A. 2002. Treatment of recurrent hepatitis B infection in liver transplant recipients. Liver Transpl.8:S74-S81.","journal-title":"Liver Transpl."},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.9.3013-3016.1999"},{"key":"e_1_3_2_62_2","first-page":"586","volume":"124","year":"2003","unstructured":"Van Bommel, F., A. Schernick, U. Hopf, and T. Berg. 2003. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation. Gastroenterology124:586-587.","journal-title":"Gastroenterology"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20464"},{"key":"e_1_3_2_64_2","first-page":"507","volume":"36","year":"2002","unstructured":"van Bommel, F., T. Wunsche, D. Schurmann, and T. Berg. 2002. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology36:507-508.","journal-title":"Hepatology"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00239-5"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510280629"},{"key":"e_1_3_2_67_2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2002.34740","volume":"36","year":"2002","unstructured":"Yang, H., C. E. Westland, W. E. Delaney IV, E. J. Heathcote, V. Ho, J. Fry, C. Brosgart, C. S. Gibbs, M. D. Miller, and S. Xiong. 2002. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology36:464-473.","journal-title":"Hepatology"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2000.00192.x"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2000.00210.x"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.7.1326"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.24.11754-11763.2000"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.8.1947"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00654-08","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00654-08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T12:11:53Z","timestamp":1684498313000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00654-08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":71,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["10.1128\/AAC.00654-08"],"URL":"https:\/\/doi.org\/10.1128\/aac.00654-08","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"2008-05-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-07-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}